168 related articles for article (PubMed ID: 37444629)
1. Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.
Andrikopoulou A; Theofanakis C; Markellos C; Kaparelou M; Koutsoukos K; Apostolidou K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F; Liontos M
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444629
[TBL] [Abstract][Full Text] [Related]
2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
4. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
5. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
[TBL] [Abstract][Full Text] [Related]
6. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
[TBL] [Abstract][Full Text] [Related]
7. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
10. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study.
Wang D; Zhang G; Peng C; Shi Y; Shi X
J Ovarian Res; 2021 Mar; 14(1):49. PubMed ID: 33771198
[TBL] [Abstract][Full Text] [Related]
11. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
12. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Haldar K; Kehoe S; Lawrie TA
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
[TBL] [Abstract][Full Text] [Related]
14. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
15. What is the optimal treatment for obese patients with advanced ovarian carcinoma?
Worley MJ; Guseh SH; Rauh-Hain JA; Esselen KM; Muto MG; Feltmate CM; Berkowitz RS; Del Carmen MG; Schorge JO; Horowitz NS
Am J Obstet Gynecol; 2014 Sep; 211(3):231.e1-9. PubMed ID: 24704062
[TBL] [Abstract][Full Text] [Related]
16. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
17. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Chen X
Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
[TBL] [Abstract][Full Text] [Related]
18. Upfront debulking surgery or delayed surgery after neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer: Comparison of survival from a noncancer center in India.
Shekhar S; Singh P; Vishnoi JR; Goel S; Pareek P; Sharma C; Goyal M; Yadav G; Jhirwal M; Soni S; Misra S
Indian J Cancer; 2023 Aug; ():. PubMed ID: 38090972
[TBL] [Abstract][Full Text] [Related]
19. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
[TBL] [Abstract][Full Text] [Related]
20. No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study.
Lyu M; Lu J; Shen Y; Chen Q; Deng F; Wang J
Front Surg; 2022; 9():997344. PubMed ID: 36171817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]